Abstract:
Platelet-rich plasma (PRP), a blood product containing high concentrations of platelets, has been increasingly used for the treatment of a number of diseases because of its anti-inflammatory and regenerative properties. PRP is generally obtained from the patient\'s own peripheral blood when used in clinical applications, but allogeneic PRP extracted from umbilical cord blood has also attracted attention due to its unique advantages. The main purpose of this narrative review was to summarize the research and clinical application of cord blood-derived PRP (CB-PRP) in the treatment of diseases up to April 2024. This review also discusses the differences between CB-PRP and autologous PRP (A-PRP). A thorough search of PubMed® and Clinicaltrials.gov identified 13 articles and four clinical trials. To date, CB-PRP has been primarily studied in the fields of orthopaedics, dermatology, neurology, obstetrics/gynaecology and ophthalmology. This is likely to be because this research is relatively novel. Considering the differences between the characteristics of A-PRP and CB-PRP, it is thought that CB-PRP might hold more promise for broader applications in the future.
摘要:
富血小板血浆(PRP),含有高浓度血小板的血液制品,由于其抗炎和再生特性,已越来越多地用于治疗多种疾病。在临床应用中,PRP通常从患者自身的外周血中获得,但从脐带血中提取的同种异体PRP也因其独特的优势而备受关注。本综述的主要目的是总结截至2024年4月脐带血来源的PRP(CB-PRP)在疾病治疗中的研究和临床应用。本文还讨论了CB-PRP和自体PRP(A-PRP)的差异。对PubMed®和Clinicaltrials.gov的彻底搜索确定了13篇文章和4项临床试验。迄今为止,CB-PRP主要在骨科领域进行了研究,皮肤病学,神经学,妇产科和眼科。这可能是因为这项研究相对新颖。考虑到A-PRP和CB-PRP特性的差异,认为CB-PRP在未来更广泛的应用中可能会有更多的希望。